Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  The Lancet

• Publication date

  2005-06-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0140-6736(05)66553-1PMID 15964447
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Valacyclovir For Cytomegalovirus Prophylaxis Reduces The Risk Of Acute Renal Allograft Rejection: A Randomized Comparison With Oral Ganciclovir And Deferred Therapy

  2004cited by this paper
• Protective Roles of Polyethylene Glycol and Trimetazidine against Cold Ischemia and Reperfusion Injuries of Pig Kidney Graft

  2004cited by this paper
• Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors

  2004cited by this paper
• Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant Recipients

  2004cited by this paper
• Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients

  2003cited by this paper
• The Registry of the International Society for Heart and Lung Transplantation: Twentieth Official adult lung and heart-lung transplant report--2003.

  2003cited by this paper
• Measuring inconsistency in meta-analyses

  2003cited by this paper
• Predictors of mortality following heart transplantation: Spanish Registry of Heart Transplantation 1984-2001.

  2003cited by this paper
• The Association of Cytomegalovirus Sero‐Pairing with Outcomes and Costs Following Cadaveric Renal Transplantation Prior to the Introduction of Oral Ganciclovir CMV Prophylaxis

  2003cited by this paper
• The registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report--2003.

  2003cited by this paper
• Valacyclovir prevention of cytomegalovirus reactivation after heart transplantation: a randomized trial.

  2002cited by this paper
• A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation

  2002cited by this paper
• Valacyclovir provides optimum acyclovir exposure for prevention of cytomegalovirus and related outcomes after organ transplantation.

  2002cited by this paper
• Meta-analysis of prophylaxis of CMV disease in solid organ transplantation: is Ganciclovir a superior agent to Acyclovir?

  2001cited by this paper
• Management of cytomegalovirus infection and disease after solid-organ transplantation.

  2001cited by this paper
• Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis

  2000cited by this paper
• High‐dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients

  1999cited by this paper
• A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients.

  1999cited by this paper
• Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

  1999cited by this paper
• Role of CMV in transplant coronary artery disease and survival after heart transplantation.

  1999cited by this paper
• Effectiveness of deferred therapy with ganciclovir in renal allograft recipients with cytomegalovirus disease.

  1998cited by this paper
• A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.

  1998cited by this paper
• Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation.

  1998cited by this paper
• Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation.

  1998cited by this paper
• Incidence of cytomegalovirus disease in renal transplantation without antilymphocyte induction: is prophylaxis necessary?

  1998cited by this paper
• Clinical practice guidelines: prevention of cytomegalovirus disease after renal transplantation.

  1998cited by this paper
• Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis.

  1998cited by this paper
• Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV‐seropositive liver transplant recipients

  1997cited by this paper
• The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

  1997cited by this paper
• Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post‐kidney transplant patients *

  1997cited by this paper
• Effect of Cytomegalovirus Infection Status on First-Year Mortality Rates among Orthotopic Liver Transplant Recipients

  1997cited by this paper
• Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients.

  1997cited by this paper
• Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children.

  1997cited by this paper
• Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database.

  1997cited by this paper
• Nonalcoholic Steatohepatitis

  1997cited by this paper
• CYTOMEGALOVIRUS AND DEATH IN LIVER TRANSPLANTATION. AUTHORS REPLY

  1997cited by this paper
• Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipients

  1997cited by this paper
• Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients

  1997cited by this paper
• Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group [corrected].

  1997cited by this paper
• Impact of high-dose oral acyclovir prophylaxis on cytomegalovirus (CMV) disease in CMV high-risk renal transplant recipients.

  1996cited by this paper
• Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.

  1996cited by this paper
• A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation.

  1995cited by this paper
• Preemptive ganciclovir therapy in cytomegalovirus-seropositive renal transplants recipients.

  1995cited by this paper
• Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Cytomegalovirus Antibody-Positive Renal Transplant Recipients

  1995cited by this paper
• Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients.

  1995cited by this paper
• Prophylactic treatment of cytomegalovirus primary infection with ganciclovir in renal transplant recipients.

  1995cited by this paper
• Identifying relevant studies for systematic reviews.

  1994cited by this paper
• Cytomegalovirus (CMV) prophylaxis by acyclovir in pre‐transplant CMV‐positive renal transplant recipients

  1994cited by this paper
• A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation.

  1994cited by this paper
• Advances in understanding cytomegalovirus infection after transplantation.

  1994cited by this paper
• A PROSPECTIVE RANDOMIZED TRIAL COMPARING SEQUENTIAL GANCICLOVIR‐HIGH DOSE ACYCLOVIR TO HIGH DOSE ACYCLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN ADULT LIVER TRANSPLANT RECIPIENTS

  1994cited by this paper
• Systematic Reviews: Identifying relevant studies for systematic reviews

  1994cited by this paper
• Effect of prophylactic ganciclovir on cytomegalovirus infection in renal transplant recipients.

  1993cited by this paper
• Viral prophylaxis in hepatic transplantation: preliminary report of a randomized trial of acyclovir and gancyclovir.

  1993cited by this paper
• Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients.

  1993cited by this paper
• Controlled trial of prophylactic versus therapeutic use of ganciclovir after liver transplantation in adults

  1993cited by this paper
• SYMPTOMATIC CYTOMEGALOVIRUS DISEASE IN THE CYTOMEGALOVIRUS ANTIBODY SEROPOSITIVE RENAL TRANSPLANT RECIPIENT TREATED WITH OKT31,2

  1992cited by this paper
• A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation.

  1992cited by this paper
• A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts.

  1989cited by this paper

• Accurate prediction of cytomegalovirus disease through optimized viral load cut-offs in intermediate-risk kidney transplant recipients.

  2026cites this paper
• Recent advances in human cytomegalovirus: a comprehensive review of pathogenic mechanisms, virus-host interactions, and antiviral strategies

  2026cites this paper
• Molecular mechanisms of HCMV-driven vascular remodeling and its significance in cardiovascular diseases

  2025cites this paper
• Transplant centers’ prophylaxis and monitoring strategies: a key determinant of current herpes and polyomavirus incidences – results from the DZIF kidney transplant cohort

  2025cites this paper
• Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.

  2024cites this paper
• Prevention of Cytomegalovirus Infection in Solid Organ Transplant Recipients: Guidelines by the Korean Society of Infectious Diseases and the Korean Society for Transplantation

  2024cites this paper
• Gastrointestinal Cytomegalovirus Infection in a Transplantation Recipient With a Negative Serum Viral Load: Case Report.

  2024cites this paper
• Efficacy and Safety of Mycophenolate Mofetil In De Novo Renal Transplantation in a Retrospective Cohort of Transplant Recipients in Colombia-Esmitren Study.

  2024cites this paper
• Efficacy of valganciclovir prophylaxis in kidney transplant recipients following low-dose rituximab induction therapy: a multicenter retrospective study

  2024cites this paper
• Cytomegalovirus-Specific T-Cell-Receptor-like Antibodies Target In Vivo-Infected Human Leukocytes Inducing Natural Killer Cell-Mediated Antibody-Dependent Cellular Cytotoxicity

  2024cites this paper
• Analysis of the Association Between Pathogen Exposure and the Risk of Dementia

  2024cites this paper
• Infectious Complications After A Liver Transplant

  2023cites this paper
• A new direction for cytomegalovirus prophylaxis among transplant recipients: Benefits and nonviral outcomes of letermovir use as primary CMV prophylaxis

  2023cites this paper
• Cancer and Infection Screening in Potential Living Donors.

  2022cites this paper
• Indirect effects of cytomegalovirus infection: Implications for vaccine development

  2022cites this paper
• Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV

  2022cites this paper
• Association Between Cytomegalovirus Serostatus, Antiviral Therapy, and Allograft Survival in Pediatric Heart Transplantation

  2022cites this paper
• Cytomegalovirus seroprevalence, infection, and disease in Chinese thoracic organ transplant recipients: a retrospective cohort study

  2022cites this paper
• Polygenic Innate Immunity Score to Predict the Risk of Cytomegalovirus Infection in CMV D+/R- Transplant Recipients. A Prospective Multicenter Cohort Study

  2022cites this paper
• Effect of Sirolimus vs. Everolimus on CMV-Infections after Kidney Transplantation—A Network Meta-Analysis

  2022cites this paper
• Cytomegalovirus DNA in non-glioblastoma multiforme brain tumors of infants

  2021cites this paper
• Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients

  2021cites this paper
• Opposite effects of cytomegalovirus UL54 exonuclease domain mutations on acyclovir and cidofovir susceptibility.

  2021cites this paper
• Cytomegalovirus Infection in Kidney Transplant Recipients

  2021cites this paper
• Assessment of Risk Factors and Outcome of Early Versus Late Cytomegalovirus Infection Infection in Living-related D+/R + Renal Allograft Recipients

  2021cites this paper
• Epidemiology and long‐term outcomes of cytomegalovirus DNAemia and disease in pediatric solid organ transplant recipients

  2021cites this paper
• Uterine Transplantation: Review of Livebirths and Reproductive Implications

  2021cites this paper
• Efficacy and safety of conventional antiviral agents in preventive strategies for cytomegalovirus infection after kidney transplantation: a systematic review and network meta‐analysis

  2021cites this paper
• The risk factor analysis and treatment experience in pneumocystis jirovecii pneumonia after kidney transplantation

  2020cites this paper
• Clinical Recommendations of the Russian Gastroenterological Association on Diagnosis and Treatment of Infectious Esophagitis

  2020cites this paper
• Cytomegalovirus antibody levels and mortality among hospitalised elderly patients

  2020cites this paper
• Impact of late‐onset cytomegalovirus infection in the development of cardiac allograft vasculopathy in heart transplant recipients

  2020cites this paper
• Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential

  2020cites this paper
• Reply to “CMV merits further evolutionary and biological view”

  2020cites this paper
• Single-cell Approach to Generate Functional TCR-Ts: A Potential Accelerator of TCR-T Cell Therapy for Infectious Diseases

  2020cites this paper
• Kidney function of Japanese children undergoing kidney transplant with preemptive therapy for cytomegalovirus infection

  2020cites this paper
• The Role of Human Cytomegalovirus Infection in Glioblastoma Multiforme Pathogenesis: Review of the Literature

  2020cites this paper
• Hepatitis A and Other Viral Infections

  2020influential citation
• Management of Antimicrobial Agents in Abdominal Organ Transplant Patients in Intensive Care Unit

  2020cites this paper
• Cytomegalovirus disease in de novo kidney-transplant recipients: comparison of everolimus-based immunosuppression without prophylaxis with mycophenolic acid-based immunosuppression with prophylaxis

  2020cites this paper
• Revisiting cytomegalovirus serostatus and replication as risk factors for inferior long-term outcomes in the current era of renal transplantation.

  2020cites this paper
• Diagnostic and therapeutic approach to infectious diseases in solid organ transplant recipients

  2019cites this paper
• Improving our mechanistic understanding of the indirect effects of CMV infection in transplant recipients

  2019cites this paper
• The Development of a Novel Algorithm for Detection of Common Bacterial, Viral and Fungal Aetiologic Agents of Meningoencephalitis

  2019cites this paper
• Increased Risk of Infectious Complications in Older Patients With Indolent Non-Hodgkin Lymphoma Exposed to Bendamustine

  2019cites this paper
• Immunosuppression and Treatment of Rejection in Uterus Transplantation: Current Practice and Future Potential

  2019cites this paper
• Evaluation of a Cytomegalovirus Prophylaxis Protocol in Cytomegalovirus-IgG Positive Renal Transplant Recipients (R+).

  2019cites this paper
• Importance of molecular diagnostic of viral infections in renal transplant recipients

  2019cites this paper
• Infections in Limbs, Integuments, and Face Transplantation

  2019cites this paper
• Efficacité antivirale et tolérance d’un régime d’immunosuppression à base d’everolimus et tacrolimus faible dose en transplantation rénale

  2019cites this paper
• Risk of cytomegalovirus transmission by blood products after solid organ transplantation

  2019cites this paper
• Pre-transplant assessment of pp65-specific CD4 T cell responses identifies CMV-seropositive patients treated with rATG at risk of late onset infection.

  2019cites this paper
• Specific T-cell receptor gene transfer enhances immune response: A potential therapeutic strategy for the control of human cytomegalovirus infection in immunocompromised patients.

  2019cites this paper
• Cytokine-Mediated Induction and Regulation of Tissue Damage During Cytomegalovirus Infection

  2019cites this paper
• University of Groningen Importance of molecular diagnostic of viral infections in renal transplant recipients Rurenga-Gard, Lilli

  2019cites this paper
• Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase‐producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia

  2019influential citation
• ESITRA-SEIMC / REIPI recommendations for the management of cytomegalovirus nfection in solid-organ transplant patients

  2019cites this paper
• Impact of electronic health record‐based, pharmacist‐driven valganciclovir dose optimization in solid organ transplant recipients

  2018cites this paper
• Primary Epstein-Barr virus infection.

  2018cites this paper
• Cytomegalovirová a polyomavirová infekce po transplantaci ledviny

  2018cites this paper
• Association of cytomegalovirus and Epstein-Barr virus with cognitive functioning and risk of dementia in the general population: 11-year follow-up study.

  2018cites this paper
• Cytomegalovirus mismatch still negatively affects patient and graft survival in the era of routine prophylactic and preemptive therapy: A paired kidney analysis

  2018cites this paper
• Pharmacologic and immunologic management of cytomegalovirus infection after solid organ and hematopoietic stem cell transplantation

  2018cites this paper
• Sodium Polystyrene Sulfonate and Cytomegalovirus-Associated Hemorrhagic Duodenitis: More than Meets the Eye

  2018cites this paper
• [Heart transplantation and infection].

  2018cites this paper
• Prevention and Treatment of Cytomegalovirus Infections in Solid Organ Transplant Recipients.

  2018cites this paper
• Late Infectious Complications after Liver Transplantation in Children

  2018cites this paper
• New Developments in the Management of Cytomegalovirus Infection After Transplantation

  2018cites this paper
• Systematic review of ganciclovir pharmacodynamics during the prevention of cytomegalovirus infection in adult solid organ transplant recipients

  2018cites this paper
• Identification of Elite Neutralizers With Broad and Potent Neutralizing Activity Against Human Cytomegalovirus (HCMV) in a Population of HCMV-Seropositive Blood Donors

  2018cites this paper
• Large-Scale Screening of HCMV-Seropositive Blood Donors Indicates that HCMV Effectively Escapes from Antibodies by Cell-Associated Spread

  2018cites this paper
• DNA- In Situ Localization of Human Cytomegalovirus and Immunohistochemical Targeting of Protein Expression of p21 Gene Sequence in Tissues from a Group of Iraqi Patients with Non-Hodgkin’s lymphoma

  2018cites this paper
• Levels of anti-CMV antibodies are modulated by the frequency and intensity of virus reactivations in kidney transplant patients

  2018cites this paper
• Cytomegalovirus infection after kidney transplantation and long-term graft loss

  2017cites this paper
• Immunomodulation by hyperimmunoglobulins after solid organ transplantation: Beyond prevention of viral infection.

  2017cites this paper
• Sero-Detection of Cytomegalovirus and Rubella Virus IgG Antibodies Among Sudanese Pregnant Women in Khartoum State-Sudan

  2017cites this paper
• Impaired polyfunctionality of CD8+ T cells in severe sepsis patients with human cytomegalovirus reactivation

  2017cites this paper
• Risk factors, survival, and impact of prophylaxis length in cytomegalovirus‐seropositive lung transplant recipients: A prospective, observational, multicenter study

  2017cites this paper
• Renal association clinical practice guideline in post-operative care in the kidney transplant recipient

  2017cites this paper
• Cytomégalovirus humain, mutations de résistance et nouvelles cibles thérapeutiques

  2017cites this paper
• Infection du donneur par le CMV et transplantation rénale : impact sur la réponse immunitaire spécifique et sur la survie des greffons

  2017cites this paper
• Praćenje citomegalovirusne infekcije u bolesnika s bubrežnim presatkom

  2017cites this paper
• Role of Secondary Prophylaxis With Valganciclovir in the Prevention of Recurrent Cytomegalovirus Disease in Solid Organ Transplant Recipients

  2017cites this paper
• Assessment of cytomegalovirus and cell-mediated immunity for predicting outcomes in non-HIV-infected patients with Pneumocystis jirovecii pneumonia

  2017cites this paper
• Infectious Complications and Malignancies Arising After Liver Transplantation.

  2017cites this paper
• Letermovir for the management of cytomegalovirus infection

  2017cites this paper
• CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor

  2017cites this paper
• 153 – Drugs for Herpesvirus Infections

  2017cites this paper
• Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients

  2017cites this paper
• Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.

  2017cites this paper
• Cytomegalovirus infection after kidney transplantation and long-term graft loss.

  2017influential citation
• Investigating and exploiting the latency-associated expression of the human cytomegalovirus gene US28 in early myeloid lineage cells.

  2017cites this paper
• Manipulation of Viral MicroRNAs as a Potential Antiviral Strategy for the Treatment of Cytomegalovirus Infection

  2017cites this paper
• Technology Medicine Open Access book

  2017cites this paper
• Is There a Role for Opportunistic Infection Prophylaxis in Pemphigus? An Expert Survey

  2017cites this paper
• Experimental and computational studies on the effects of valganciclovir as an antiviral drug on calf thymus DNA

  2017cites this paper
• Potential of small-molecule fungal metabolites in antiviral chemotherapy

  2017cites this paper
• Cytomegalovirus transmission in pediatric renal transplant recipients during the window period

  2016cites this paper
• Histopathologic identification and pattern recognition of common viral infections in the general pathology practice: An illustrated review

  2016cites this paper
• Pro: Meta-analysis: the case for.

  2016cites this paper